Patents Assigned to IMMUNOMET THERAPEUTICS INC
  • Patent number: 11826324
    Abstract: Provided are a pharmaceutical composition for preventing or treating inflammatory disease, autoimmune disease, graft rejection responses, or combinations thereof, the pharmaceutical composition including a compound represented by Formula 1, or a stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof, and a method using the pharmaceutical composition. The pharmaceutical composition and the method can be used to effectively prevent or treat inflammatory disease, autoimmune disease, graft rejection responses, or combinations thereof.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: November 28, 2023
    Assignees: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY, IMMUNOMET THERAPEUTICS INC.
    Inventors: Jungsik Song, Beom Seok Kim, Sang Jun Ha, Ji Min Son
  • Patent number: 11572341
    Abstract: The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: February 7, 2023
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Hong Woo Kim, Jae Kap Jeong, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Sung Wuk Kim
  • Patent number: 11465989
    Abstract: The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: October 11, 2022
    Assignee: ImmunoMet Therapeutics, Inc.
    Inventors: Sung Wuk Kim, Hong Woo Kim, Sang Hee Yoo, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Young Woo Lee, Mi Jeong Kim, Woong Cho
  • Publication number: 20210113497
    Abstract: Provided are a pharmaceutical composition for preventing or treating inflammatory disease, autoimmune disease, graft rejection responses, or combinations thereof, the pharmaceutical composition including a compound represented by Formula 1, or a stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof, and a method using the pharmaceutical composition. The pharmaceutical composition and the method can be used to effectively prevent or treat inflammatory disease, autoimmune disease, graft rejection responses, or combinations thereof.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 22, 2021
    Applicants: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY, IMMUNOMET THERAPEUTICS INC.
    Inventors: Jungsik SONG, Beom Seok KIM, Sang Jun HA, Ji Min SON
  • Patent number: 10626085
    Abstract: The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: April 21, 2020
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Hong Woo Kim, Jae Kap Jeong, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Sung Wuk Kim
  • Patent number: 10590081
    Abstract: The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: March 17, 2020
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Sung Wuk Kim, Hong Woo Kim, Sang Hee Yoo, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Young Woo Lee
  • Publication number: 20200038347
    Abstract: Provided are a pharmaceutical composition for preventing or treating inflammatory disease, autoimmune disease, graft rejection responses, or combinations thereof, the pharmaceutical composition including a compound represented by Formula 1, or a stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof, and a method using the pharmaceutical composition. The pharmaceutical composition and the method can be used to effectively prevent or treat inflammatory disease, autoimmune disease, graft rejection responses, or combinations thereof.
    Type: Application
    Filed: January 23, 2018
    Publication date: February 6, 2020
    Applicants: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY, IMMUNOMET THERAPEUTICS INC.
    Inventors: Jungsik SONG, Beom Seok KIM, Sang Jun HA, Ji Min SON
  • Patent number: 10376480
    Abstract: A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK? and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: August 13, 2019
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Chang Hee Min, Young Woong Kim, Min Seok Kang, Byung Kyu Oh, Se Hwan Park, Yong Eun Kim, Duck Kim, Ji Sun Lee, Ju Hoon Oh
  • Patent number: 10252996
    Abstract: The present invention provides an N1-cyclic amine-N5-substituted biguanide derivative compound represented by Formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient. The biguanide derivatives have an effect of inhibiting cancer cell proliferation, cancer metastasis and cancer recurrence by activation of AMPK, even when administered in a small dose compared with conventional drugs.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: April 9, 2019
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Chang Hee Min, Yong Eun Kim, Byung Kyu Oh, Ji Sun Lee, Hye Jin Heo, Ju Hoon Oh, Woong Cho
  • Patent number: 10221190
    Abstract: The present invention relates to biguanide compounds and use thereof, more particularly, to biguanide derivatives exhibiting excellent effects for inhibition of cancer cell proliferation and inhibition of cancer metastasis and recurrence, a method for preparing the same, a pharmaceutical composition containing the same as an active ingredient, and a method of prevention or treatment of cancer comprising the step of administering an effective amount of the composition to a subject in need thereof.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: March 5, 2019
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Hong Woo Kim, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Jae Kap Jeong, Ji Hyun Park, Seo-il Kim, Young Woo Lee
  • Patent number: 10058558
    Abstract: The present invention provides a novel use of N1-cyclic amine-N5-substituted biguanide derivatives for preparing a medicine for preventing or treating fibrosis. The N1-cyclic amine-N5-substituted biguanide derivatives according to the present invention are capable of effectively inhibiting fibrosis by effectively suppressing the EMT.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: August 28, 2018
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Sung Wuk Kim, Soon Im Lee, Yeon Jung Song, Min Jae Shin, Kook Hwan Oh, Kyung Don Ju, Eun Kyoung Shin, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Min Jeong Kim, Hye Soun Eum
  • Patent number: 9993446
    Abstract: A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK? and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: June 12, 2018
    Assignee: Immunomet Therapeutics Inc.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Chang Hee Min, Young Woong Kim, Min Seok Kang, Byung Kyu Oh, Se Hwan Park, Yong Eun Kim, Duck Kim, Ji Sun Lee, Ju Hoon Oh
  • Publication number: 20180044283
    Abstract: The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.
    Type: Application
    Filed: November 20, 2015
    Publication date: February 15, 2018
    Applicant: ImmunoMet Therapeutics Inc.
    Inventors: Hong Woo KIM, Jae Kap JEONG, Ji Sun LEE, Hye Jin HEO, Hong Bum LEE, Ji Ae KOOK, Sung Wuk KIM
  • Patent number: 9884821
    Abstract: The present invention provides an N1-cyclic amine-N5-substituted biguanide derivative compound represented by Formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient. The biguanide derivatives have an effect of inhibiting cancer cell proliferation, cancer metastasis and cancer recurrence by activation of AMPK, even when administered in a small dose compared with conventional drugs.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: February 6, 2018
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Chang Hee Min, Yong Eun Kim, Byung Kyu Oh, Ji Sun Lee, Hye Jin Heo, Ju Hoon Oh, Woong Cho
  • Publication number: 20170305861
    Abstract: The present invention relates to heteroaryl compounds comprising nitrogen and use thereof, and more specifically to compounds which exhibit a remarkable effect on inhibiting proliferation of cancer cells and metastasis and recurrence of cancer, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compounds according to the present invention exhibit a remarkable effect on inhibiting proliferation of cancer cells and metastasis and recurrence of cancer with a reduced dose compared to that of existing drugs. Accordingly, the compounds can be effectively used for treating various types of cancer, such as uterine cancer, breast cancer, gastric cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, pancreatic cancer, renal cancer, prostate cancer, bladder cancer, and liver cancer, and for inhibiting proliferation of cancer cells and metastasis of cancer.
    Type: Application
    Filed: April 25, 2017
    Publication date: October 26, 2017
    Applicant: ImmunoMet Therapeutics, Inc
    Inventors: Sung Wuk Kim, Hong Woo Kim, SangHee Yoo, Hyunwook Kim, Hye Jin Heo, Hong Bum Lee, Jiae Kook, Young Woo Lee
  • Publication number: 20170073331
    Abstract: The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
    Type: Application
    Filed: April 17, 2015
    Publication date: March 16, 2017
    Applicant: IMMUNOMET THERAPEUTICS INC.
    Inventors: Sung Wuk Kim, Hong Woo Kim, Sang Hee Yoo, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Young Woo Lee, Mi Jeong Kim, Woong Cho
  • Patent number: 9539238
    Abstract: The present invention provides novel uses of a biguanide derivative for preventing or treating glioblastoma. The compound of Formula 1 and its pharmaceutically acceptable salts can be used for preventing and treating glioblastoma. Further, the combined treatment of the compound of Formula 1 and temozolomide can provide superior effects compared to the administration of the compound of Formula 1 alone or temozolomide alone.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: January 10, 2017
    Assignee: IMMUNOMET THERAPEUTICS, INC
    Inventors: Seok Gu Kang, Ji Hyun Lee, Jong Hee Chang, Jae Ho Cheong, Jun Jeong Choi, Sung Wuk Kim, Sang Hee Yoo, Hong Woo Kim, Soon Im Lee
  • Patent number: 9540325
    Abstract: An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: January 10, 2017
    Assignee: Immunomet Therapeutics, Inc.
    Inventors: Sung Wuk Kim, Chang Hee Min, Se Hwan Park, Duck Kim, Ji Sun Lee, Yong Eun Kim, Ju Hoon Oh
  • Patent number: 9464042
    Abstract: A biguanide derivative compound with N4-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK and inhibition of cancer cell proliferation in a low dose, compared with conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: October 11, 2016
    Assignee: IMMUNOMET THERAPEUTICS INC.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Chang Hee Min, Se Hwan Park, Yong Eun Kim, Duck Kim, Ji Sun Lee, Ju Hoon Oh
  • Patent number: 9416098
    Abstract: A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK? and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: August 16, 2016
    Assignee: IMMUNOMET THERAPEUTICS INC.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Chang Hee Min, Young Woong Kim, Min Seok Kang, Byung Kyu Oh, Se Hwan Park, Yong Eun Kim, Duck Kim, Ji Sun Lee, Ju Hoon Oh